AcuCort invites shareholders, investors, analysts and the media to a Capital Markets Day in Stockholm on 13 October. During the morning, the company will present its path forward, with a focus on its international expansion in Europe and the US.
AcuCort is in an intensive phase of expansion. In Europe, the company has entered into a commercial agreement with Glenmark Pharmaceuticals covering six markets, with launches planned for 2027. In parallel, AcuCort is preparing a New Drug Application (NDA) for Zeqmelit® in the US.
During the Capital Markets Day, CEO Jonas Jönmark, Business Development Director Anna Chérouvrier Hansson and Strategic Alliance Manager Carl Frisk will provide further insight into Zeqmelit®, the company's international partnerships, its experience in the Nordic market and its plans for continued expansion in Europe and the US.
Date: Tuesday, 13 October 2026
Venue: Investor Studios, Stockholm
Hötorgsskrapa 3, 7th floor
Entrance via Mäster Samuelsgatan 42, Sveavägen 9 or Sergelgatan 8-10
Programme
09.30 Coffee and registration
10.00 Presentations and Q&A
11.30-12.00 Networking
Registration:
ir.acucort.se/kmd
For further information:
Jonas Jönmark, CEO, AcuCort AB
Phone: 070 365 5400
E-mail: jonas.jonmark@acucort.se
About AcuCort AB (publ)
AcuCort has developed and is commercializing Zeqmelit®, a new rapidly dissolving oral film placed on the tongue, based on the well-known cortisone substance dexamethasone. The drug is a smart product in a new, innovative, patented, and user-friendly administration form primarily for the treatment of severe and acute allergic reactions, croup in children, nausea and vomiting during chemotherapy, and for the treatment of patients with COVID-19 requiring supplemental oxygen therapy. Zeqmelit® is approved in Sweden, Denmark, Norway, and Finland, where the product is also marketed. AcuCort (ticker: ACUC) is listed on the Spotlight Stock Market. Visit www.acucort.se for more information.